Physical training for McArdle disease

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Quinlivan, Rosaline ^a   Vissing, John ^b   Hilton Jones, David ^c   Buckley, John ^d  

^a ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AEROBIC CAPACITY; CELL HETEROGENEITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DATA ANALYSIS; DNA DETERMINATION; EXERCISE; GENE MUTATION; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; INFORMATION PROCESSING; INTENSIVE CARE; MEDICAL RESEARCH; MORTALITY; MUSCLE BIOPSY; NONSENSE MUTATION; PHENOTYPE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TRAINING; TREATMENT OUTCOME;

EID: 70049099139     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007931     Document Type: Review

References (19)

1. Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. Journal of Neurology, Neurosurgery and Psychiatry 2008;79(12):1359-1363 (Pubitemid 351831456)
2. Andreu A, Nogales-Gadea, Cassandrini D, Arenas J, Bruno C. McArdle disease: molecular genetic update. Acta Myologica 2007;26(1):53-57 (Pubitemid 47400726)
3. Aquaron R, Berge-Lefranc JL, Pellissier JF, Montfort MF, Mayan M, Figarella-Branger D, et al.Molecular characterisation of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: identification of 10 new mutations. absence of genotype-phenotype correlation. Neuromuscular Disorders 2007;17(3):235-241 (Pubitemid 46420773)
4. Bartram C, Edwards RHT, Clague J, Beynon R. McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Human Molecular Genetics 1993;2(8):1291-1293 (Pubitemid 23245012)
5. Borg G. Borg's perceived exertion and pain scales. Human Kinetics Publishers, 1998.
6. De Stefano N, Argov Z, Matthews PM, Karparti G, Arnold DL. Impairment of muscle mitochondrial oxidative metabolism in McArdle's Disease. Muscle & Nerve 1996;19(6):764-769 (Pubitemid 26134588)
7. Deschauer M, Morgenroth A, Joshi PR, Glaser D, Chinnery PF, Aasley J, et al.Analysis of spectrum and frequencies of mutations in McArdle Disease: identification of 13 novel mutations. Journal of Neurology 2007;254:797-802. (Pubitemid 47012462)
8. Gomez-Gallego F, Santiago C, Morán M, Pérez M, Maté-Muñoz JL, Fernandez Del Valle M, et al.The I allele of the ACE gene is associated with improvement in exercise capacity in women with McArdle disease. British Journal of Sports Medicine 2008;42(2):134-140 (Pubitemid 351271228)
9. Haller RG, Lewis SF, Cook JD, Bloomvist CG. Myophosphorylase activity impairs muscle oxidative metabolism. Annals of Neurology 1985;17(2):196-199
10. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2008.
11. Lucia A, Gomez-Gallego F, Santiago C, Perez M, Mate-Munoz J L, Chamorro-Vina C, et al.The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle's disease. Neuromuscular Disorders 2007;17(8):603-610 (Pubitemid 47030921)
12. Martinuzzi A, Sartoi E, Fanin M, Nascimbeni A, Valente L, Angelini C, et al.Phenotype modulators in myophosphorylase deficiency. Annals of Neurology 2003;53(4):497-502.
13. Ollivier K, Hogrel JY, Gomez-Merino D, Romero NB, Laforet P, Eymard B, et al.Exercise tolerance and daily life in McArdle's disease. Muscle & Nerve 2005;31:637-641 (Pubitemid 40577788)
14. Orngreen MC, Jeppesen TD, Andersen ST, Taivassalo T, Hauerslev S, Preisler N, Haller RG, van Hall G, Vissing J. Fat metabolism during exercise in people with McArdle disease. Neurology 2009;72:718-724
15. Quinlivan R, Vissing J. 144th ENMC international Workshop: Outcome measures in McArdle Disease, 29 September-1 November 2006, Naarden, The Netherlands. Neuromuscular Disorders 2007;17(6):494-498
16. R Quinlivan, R Beynon, A Martinuzzi. Pharmacological and nutritional treatment for McArdle Disease. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858]
17. Rubio JC, Gomez-Gallego F, Santiago C, Garcia-Consuegra I, Perez M, Barriopedro MI, et al.Genotype modulators of clinical severity in McArdle disease. Neuroscience Letters 2007;422(3):217-222 (Pubitemid 47077604)
18. Vissing J, Vissing SF, Maclean D, Saltin B, Quistorff B, Haller RJ. Sympathetic activation in exercise is not dependent on muscle acidosis. Direct evidence from studies in metabolic myopathies. Journal of Clinical Investigation 1998;101(8):1654-1660 (Pubitemid 28198494)
19. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. New England Journal of Medicine 2003;349(26):2503-2509 (Pubitemid 38010076)